Final agenda is now available for our 2nd Annual Drug Discovery USA Congress in Boston

Posted: 4 September 2015 | Oxford Global

Production is now complete for the 2nd Annual Drug Discovery USA Congress taking place on the 29th & 30th of October 2015 in Boston, USA…

Production is now complete for the 2nd Annual Drug Discovery USA Congress taking place on the 29th & 30th of October 2015 in Boston, USA. You can now download the final conference programme here to view who is speaking across the two days.

Our renowned speakers will explore novel peptide drug discovery, strategies for target selection and incorporating genomic technologies into discovery research. Day one features an exciting stream covering the latest screening and assay technologies, such as novel stem cell assays, exciting new phenotypic screening strategies and how to use stem and primary cells for physiologically relevant disease models. Day two will also host discussions about the latest research in the discovery chemistry field, with exciting case studies covering computational tools for gene editing and drug design as well as fragment based drug discovery case studies.

Join over 150 senior delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions. The conference will provide over 40 presentations and case studies focusing on the key issues in drug discovery and medicinal chemistry.

Our Summit will consist of 4 interactive streams:

  • Target Based Discovery
  • Screening & Assays: Enabling Technologies
  • Discovery Chemistry & Drug Design
  • Supporting Innovation: Translational Approaches & Informatics Tools

Oxford Global interviewed Matthew Wagoner, a discovery safety specialist from AstraZeneca and a confirmed speaker of the Congress.

Matthew will talk about Bromodomain And ExtraTerminal (BET) Domain Inhibitors Induce A Loss Of Intestinal Stem Cells And Villous Atrophy.

Big Pharma is keen to increase drug discovery productivity; which strategies do you think will help to increase R&D output?

“I think the strategies for increasing drug discovery productivity will be multifaceted. We do quite a bit of the traditional internal repurposing and rescue, which is a great way of accelerating a nascent project idea with more advanced chemistry. The most promising of these approaches, in my opinion, is opening up your pharmacology toolbox and clinical compound bank to academics so they can test their best hypotheses with our best molecules. AstraZeneca has done that with great success through the NIH/NCATS and MRC, with 10+ clinical and translational research projects being initiated in academia with AstraZeneca’s patient-ready compounds.”

There will be over 36 speakers presenting across the two days including:

  • Anabella Villalobos, Vice President, Pfizer
  • Frank Brown, Associate Vice President and Head, Structural Chemistry, Merck Research laboratories
  • Alan Wahl, Vice President, Research and Discovery, Ambrx
  • Omar Francone, VP, Head of Discovery Biology, Shire
  • Jean Cavallo, Associate Director, Molecular Pathology, Sanofi
  • Chris Burgey, Executive Director, Merck

Click here to review the full list of speakers:

Attending this Congress will give you?

  • Full access to the 2 days of conference presentations
  • Lunch and Refreshments during the congress
  • Access to all networking activities
  • Access to exhibition area
  • Conference workbook and online access to conference materials, notes and presentations

Download the conference programme to find out more about this two day congress:

Reserve Your Place Today!

Registration continues and with only a limited number of places available, please contact Guillaume Alonso on [email protected] or call on +44(0)1865 248 455 today.

If you’re looking to present a poster, we have limited spaces available on a strictly first come first served basis. For further information regarding our poster presentations, or to find out more about this or any of our upcoming events in our Drug Discovery series 2015 please contact Guillaume Alonso on [email protected] or call us on +44(0)1865 248455.

You can also discover even more and discuss the latest topics in the drug discovery industry and medicinal chemistry on our social media:
LinkedIn: Drug Discovery & Development Network Group

Related topics

Related organisations